Davis Polk is advising JP Morgan as financial adviser to Sequenom, Inc. in connection with its $371 million acquisition by Laboratory Corporation of America Holdings. The closing of the transaction is expected by year end and is subject to customary closing conditions, including the acquisition of a majority of Sequenom, Inc.’s outstanding shares in a cash tender offer for $2.40 per share by a subsidiary of Laboratory Corporation of America Holdings and certain regulatory approvals.

Sequenom, Inc. has developed a broad range of molecular genetic tests to provide early patient management information for obstetricians, geneticists and maternal fetal medicine specialists, including HerediT, HerediT UNIVERSAL, MaterniT GENOME, MaterniT 21 PLUS, NextView, SensiGene and VisibiliT. Laboratory Corporation of America Holdings is a leading health care diagnostics company, providing comprehensive clinical laboratory and end-to-end drug development services.

The Davis Polk corporate team includes partner Alan F. Denenberg and associate Max Brunner. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post